AbbVie (ABBV) said Friday it received approval from the US Food and Drug Administration for its antibiotic Emblaveo for the treatment of adults with complicated intra-abdominal infections.
The approval covers Emblaveo's use with metronidazole in patients who have limited or no alternative options to treat their infections, including those caused by Gram-negative bacteria which can become antimicrobial resistant, the drugmaker said.
Emblaveo will be available for commercial use in Q3, AbbVie said.
Price: 191.52, Change: -1.45, Percent Change: -0.75
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。